NICE Endorses Obecabtagene Autoleucel Therapy f...

By João L. Carapinha

November 25, 2025

NICE Backs Obecabtagene Autoleucel The National Institute for Health and Care Excellence (NICE) recommended obecabtagene autoleucel therapy, a UK-dev...
Datroway TNBC Therapy: Transforming First-Line Treatment for Metastatic Tripl...
Key Decisions on Health Technology Assessment at ACP124: Implications for Rar...
Dutch Pharmacoeconomic Redesign: Streamlined Structure and Enhanced Transpare...
Revolutionizing Pharmacoeconomic Evaluations Nederland: Zorginstituut’s...
DALY Modeling Methods for Enhanced Health Economics and Policy Analysis
Enhertu Reimbursement Analysis: Navigating Cost-Effectiveness Challenges
Implementing Health Technology Assessment in Oman
Surrogate Endpoints Guidance: New International Report Enhances HTA Practices
Reevaluating NICE’s Cost-Effectiveness Thresholds: The QALY Debate
Boosting Biopharma SMEs in Europe
NICE Rejects Donanemab for NHS Use Due to Cost Concerns
Enhancing Child Mental Health Services with Digital Interventions